|
Fusion gene ID: 22277 |
FusionGeneSummary for MOCS3_NIPAL3 |
Fusion gene summary |
Fusion gene information | Fusion gene name: MOCS3_NIPAL3 | Fusion gene ID: 22277 | Hgene | Tgene | Gene symbol | MOCS3 | NIPAL3 | Gene ID | 27304 | 57185 |
Gene name | molybdenum cofactor synthesis 3 | NIPA like domain containing 3 | |
Synonyms | UBA4 | DJ462O23.2|NPAL3 | |
Cytomap | 20q13.13 | 1p36.11 | |
Type of gene | protein-coding | protein-coding | |
Description | adenylyltransferase and sulfurtransferase MOCS3MPT synthase sulfurylaseUBA4, ubiquitin-activating enzyme E1 homologmolybdenum cofactor synthesis protein 3molybdopterin synthase sulfurylaseubiquitin-like modifier activating enzyme 4 | NIPA-like protein 3 | |
Modification date | 20180523 | 20180523 | |
UniProtAcc | O95396 | Q6P499 | |
Ensembl transtripts involved in fusion gene | ENST00000244051, | ENST00000374399, ENST00000003912, ENST00000358028, ENST00000339255, ENST00000428131, ENST00000488155, | |
Fusion gene scores | * DoF score | 1 X 1 X 1=1 | 5 X 5 X 3=75 |
# samples | 1 | 5 | |
** MAII score | log2(1/1*10)=3.32192809488736 | log2(5/75*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: MOCS3 [Title/Abstract] AND NIPAL3 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | MOCS3 | GO:0002098 | tRNA wobble uridine modification | 19017811 |
Hgene | MOCS3 | GO:0006777 | Mo-molybdopterin cofactor biosynthetic process | 15073332 |
Hgene | MOCS3 | GO:0018192 | enzyme active site formation via cysteine modification to L-cysteine persulfide | 15910006 |
Hgene | MOCS3 | GO:0034227 | tRNA thio-modification | 19017811 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | LD | BRCA | TCGA-E9-A1R7-01A | MOCS3 | chr20 | 49578110 | + | NIPAL3 | chr1 | 24798588 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
intron-intron | ENST00000244051 | ENST00000374399 | MOCS3 | chr20 | 49578110 | + | NIPAL3 | chr1 | 24798588 | + |
intron-3UTR | ENST00000244051 | ENST00000003912 | MOCS3 | chr20 | 49578110 | + | NIPAL3 | chr1 | 24798588 | + |
intron-intron | ENST00000244051 | ENST00000358028 | MOCS3 | chr20 | 49578110 | + | NIPAL3 | chr1 | 24798588 | + |
intron-intron | ENST00000244051 | ENST00000339255 | MOCS3 | chr20 | 49578110 | + | NIPAL3 | chr1 | 24798588 | + |
intron-intron | ENST00000244051 | ENST00000428131 | MOCS3 | chr20 | 49578110 | + | NIPAL3 | chr1 | 24798588 | + |
intron-intron | ENST00000244051 | ENST00000488155 | MOCS3 | chr20 | 49578110 | + | NIPAL3 | chr1 | 24798588 | + |
Top |
FusionProtFeatures for MOCS3_NIPAL3 |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
MOCS3 | NIPAL3 |
Plays a central role in 2-thiolation of mcm(5)S(2)U attRNA wobble positions of cytosolic tRNA(Lys), tRNA(Glu) andtRNA(Gln). Also essential during biosynthesis of the molybdenumcofactor. Acts by mediating the C-terminal thiocarboxylation ofsulfur carriers URM1 and MOCS2A. Its N-terminus first activatesURM1 and MOCS2A as acyl-adenylates (-COAMP), then the persulfidesulfur on the catalytic cysteine is transferred to URM1 and MOCS2Ato form thiocarboxylation (-COSH) of their C-terminus. Thereaction probably involves hydrogen sulfide that is generated fromthe persulfide intermediate and that acts as nucleophile towardsURM1 and MOCS2A. Subsequently, a transient disulfide bond isformed. Does not use thiosulfate as sulfur donor; NFS1 probablyacting as a sulfur donor for thiocarboxylation reactions.{ECO:0000255|HAMAP-Rule:MF_03049, ECO:0000269|PubMed:15073332,ECO:0000269|PubMed:19017811}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for MOCS3_NIPAL3 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for MOCS3_NIPAL3 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
MOCS3 | EXOSC6, XRN2, VSX1, RSPH9, NMI, FAS, FIGF, POMK, KLC2, FBXL18, HERC4, ALX3, DYNC2H1, SACS, HSPA6, VPS16, LIN9 | NIPAL3 | ELAVL1, EDA, VPS45, LMNA |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for MOCS3_NIPAL3 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for MOCS3_NIPAL3 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | NIPAL3 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |